Value through Innovation21 May 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

27.01.2015

New large-scale study to investigate effect of tiotropium + olodaterol Respimat® on exacerbations in COPD

- For media outside the US, the UK and Canada
19.01.2015

OFEV® (nintedanib*) approved in the EU for the treatment of IPF

- For media outside UK, US and Canada
15.01.2015

Boehringer Ingelheim and Sanofi enter into a strategic contract manufacturing alliance to produce biopharmaceuticals

15.01.2015

35 partners from industry and academia to join European research initiative for the prevention of Alzheimer’s dementia

14.01.2015

Boehringer Ingelheim and Vanderbilt University join forces to develop new Ras inhibitors for cancer treatment

13.01.2015

Boehringer Ingelheim and Yale University collaborate to investigate novel immunotherapy targets across several therapeutic areas

12.01.2015

The Lancet Oncology publishes Phase III data showing Giotrif® (afatinib*) significantly extended overall survival of lung cancer patients with the most common EGFR mutation over chemotherapy

- For media outside UK, US and Canada only
22.12.2014

New vaccine against Bovine Viral Diarrhea: Boehringer Ingelheim receives European marketing authorization for Bovela®

15.12.2014

First trial of a novel oral anticoagulant starts in prevention of recurrent stroke due to a blood clot of undetermined source

- For Non-US/Non-UK/Non-Canadian Media
12.12.2014

Boehringer Ingelheim LUX-Breast 1 and LUX-Breast 3 data at San Antonio Breast Cancer Symposium (SABCS)

- For Media Outside the UK, US and Canada Only
09.12.2014

New data show specific antidote idarucizumab* reverses dabigatran-induced anticoagulation also in elderly and renally impaired volunteers

- For Non-US/Non-UK/Non-Canadian Media
04.12.2014

Investing in the development of innovative active ingredients: Boehringer Ingelheim opens a new technology centre in Biberach

27.11.2014

Vargatef® (nintedanib*) approved in the EU for lung cancer patients with advanced adenocarcinoma after first-line chemotherapy

- For media outside UK, US and Canada only
21.11.2014

Nintedanib* receives positive CHMP opinion in European Union for the treatment of IPF

- For media outside UK, US and Canada
19.11.2014

Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa® than with warfarin

- For Non-US/Non-UK/Non-Canadian Media
19.11.2014

New data show dabigatran-specific antidote idarucizumab* restores blood clotting mechanism in humans

- For Non-US/Non-UK/Non-Canadian Media
14.11.2014

Boehringer Ingelheim "Runs" to support vital programs in Diabetes and Stroke

07.11.2014

New subgroup analysis shows Asian non-small cell lung cancer patients with most common EGFR mutation (del19) lived significantly longer with first-line GIOTRIF® (afatinib*) compared to chemotherapy

- For Media In Asian Countries Only For Whom The Data Is Relevant For media outside the US, the UK & Canada only